Julia Forbess

Associate, Corporate  

San Francisco 415.875.2420


Julia Forbess represents public technology and biotech companies in a variety of transactional matters with an emphasis on initial public offerings and follow-on offerings in equity and convertible debt, including 144A offerings. Representative issuer side initial public offerings include Arcutis Biotherapeutics, Loxo Oncology, Morphic Holding, Stoke Therapeutics and Workday. She also represents public companies in SEC regulatory compliance and corporate governance matters. 

Representative Experience:

  • Loxo Oncology in its $8B acquisition by Eli Lilly; as well as prior follow-on offerings totaling almost $500M 
  • Dexcom in its $850M convertible senior notes offering
  • Tanium in its $200M financing
  • Audentes in its $201.3M follow-on offering ​
  • AnaptysBio in its $238.9M follow-on offering
  • Redfin in its $258.3M concurrent public offerings of stock and convertible notes
  • Underwriters in Zillow Group’s $747.5M concurrent public offerings of stock and convertible notes

While attending law school, Julia was a member of the Chicago Journal of International Law and received the Joseph Henry Beale Prize for legal writing.​​​